Peptides of human Papilloma virus for use in human T cell response inducing compositions
A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.
1. An isolated peptide comprising an amino acid sequence from 9 to 12 amino acids in length selected from the group consisting of:
AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
KLPQLCTEL (residues 18-26 of HPV16 protein E6) SEQ ID NO:2
QLCTELQTT (residues 21-29 of HPV16 protein E6) SEQ ID NO:3
LCTELQTTI (residues 22-30 of HPV16 protein E6) SEQ ID NO:4
ELQTTIHDI (residues 25-33 of HPV16 protein E6) SEQ ID NO:5
LQTTIHDII (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
TIHDIILEC (residues 29-37 of HPV16 protein E6) SEQ ID NO:7
IHDIILECV (residues 30-38 of HPV16 protein E6) SEQ ID NO:8
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
FAFRDLCIV (residues 52-60 of HPV16 protein E6) SEQ ID NO:10
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
PLCDLLIRC (residues 102-110 of HPV16 protein E6) SEQ ID NO:12
TLHEYMLDL (residues 7-15 of HPV16 protein E7) SEQ ID NO:13
MLDLQPETT (residues 12-20 of HPV16 protein E7) SEQ ID NO:15
RLCVQSTHV (residues 66-74 of HPV16 protein E7) SEQ ID NO:16
TLEDLLMGT (residues 78-86 of HPV16 protein E7) SEQ ID NO:17
LLMGTLGIV (residues 82-90 of HPV16 protein E7) SEQ ID NO:18
GTLGIVCPI (residues 85-93 of HPV16 protein E7) SEQ ID NO:19 and
TLGIVCPIC (residues 86-94 of HPV16 protein E7) SEQ ID NO:20;
wherein said amino acid sequence is derived from protein E6 or E7 of HPV16; and
wherein said peptide has the ability to bind to human MHC Class I allele HLA-A2.1.
2. An isolated peptide comprising an amino acid sequence from 9 to 12 amino acids in length selected from the group consisting of:
KLPDLCTEL (residues 13-21 of HPV18 protein E6) SEQ ID NO:21
SLQDIEITC (residues 24-32 of HPV18 protein E6) SEQ ID NO:22
LQDIEITCV (residues 25-33 of HPV18 protein E6) SEQ ID NO:23
EITCVYCKT (residues 29-37 of HPV18 protein E6) SEQ ID NO:24
KTVLELTEV (residues 36-44 of HPV18 protein E6) SEQ ID NO:25
ELTEVFEFA (residues 40-48 of HPV18 protein E6) SEQ ID NO:26
FAFKDLFVV (residues 47-55 of HPV18 protein E6) SEQ ID NO:27
DTLEKLTNT (residues 88-96 of HPV18 protein E6) SEQ ID NO:28
LTNTGLYNL (residues 93-101 of HPV18 protein E6) SEQ ID NO:29
TLQDIVLHL (residues 7-15 of HPV18 protein E7) SEQ ID NO:30
FQQLFLNTL (residues 86-94 of HPV18 protein E7) SEQ ID NO:31
QLFLNTLSF (residues 88-96 of HPV18 protein E7) SEQ ID NO:32
LFLNTLSFV (residues 89-97 of HPV18 protein E7) SEQ ID NO:33 and
LSFVCPWCA (residues 94-102 of HPV18 protein E7) SEQ ID NO:34;
wherein said amino acid sequence is derived from protein E6 or E7 of HPV18; and
wherein said peptide has the ability to bind to human MHC Class I allele HLA-A2.1.
3. An isolated peptide comprising an amino acid sequence from 9 to 12 amino acids in length selected from the group consisting of:
YRDGNPYAV (residues 61-69 of HPV16 protein E6) SEQ ID NO:35
WTGRCMSCC (residues 139-147 of HPV16 protein E6) SEQ ID NO:36
MSCCRSSRT (residues 144-152 of HPV16 protein E6) SEQ ID NO:37
TTDLYCYEQ (residues 19-27 of HPV16 protein E7) SEQ ID NO:38
EIDGPAGQA (residues 37-45 of HPV16 protein E7) SEQ ID NO:39 and
HVDIRTLED (residues 73-81 of HPV16 protein E7) SEQ ID NO:40;
wherein said amino acid sequence is derived from protein E6 or E7 of HPV16; and
wherein said peptide has the ability to bind to human MHC Class I allele HLA-A1.
4. An isolated peptide comprising an amino acid sequence from 9 to 12 amino acids in length selected from the group consisting of:
AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
KFYSKISEY (residues 75-83 of HPV16 protein E6) SEQ ID NO:48
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
RHYCYSLYG (residues 84-92 of HPV16 protein E6) SEQ ID NO:50
SLYGTTLEQ (residues 89-97 of HPV16 protein E6) SEQ ID NO:51
TTLEQQYNK (residues 93-101 of HPV16 protein E6) SEQ ID NO:52
QQYNKPLCD (residues 97-105 of HPV16 protein E6) SEQ ID NO:53
LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
HLDKKQRFH (residues 125-133 of HPV16 protein E6) SEQ ID NO:55
CMSCCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
CCRSSRTRR (residues 146-154 of HPV16 protein E6) SEQ ID NO:58
YNIVTFCCK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61 and
KCDSTLRLC (residues 60-68 of HPV16 protein E7) SEQ ID NO:62;
wherein said amino acid sequence is derived from protein E6 or E7 of HPV16; and
wherein said peptide has the ability to bind to human MHC Class I allele HLA-A3.2.
5. An isolated peptide comprising an amino acid sequence from 9 to 12 amino acids in length selected from the group consisting of:
AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
TGRCMSCCR (residues 140-148 of HPV16 protein E6) SEQ ID NO:63
CMSCCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
YNIVTFCCK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61 and
VCPICSQKP (residues 90-98 of HPV16 protein E7) SEQ ID NO:64;
wherein said amino acid sequence is derived from protein E6 or E7 of HPV16; and
wherein said peptide has the ability to bind to human MHC Class I allele HLA-A11.2.
6. An isolated peptide comprising an amino acid sequence from 9 to 12 amino acids in length selected from the group consisting of:
MHQKRTAMF (residues 1-9 of HPV16 protein E6) SEQ ID NO:65
LQTTIHDII (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
LLRREVYDF (residues 44-52 of HPV16 protein E6) SEQ ID NO:66
VYDFAFRDL (residues 49-57 of HPV16 protein E6) SEQ ID NO:67
PYAVCDKCL (residues 66-74 of HPV16 protein E6) SEQ ID NO:68
KCLKFYSKI (residues 72-80 of HPV16 protein E6) SEQ ID NO:69
EYRHYCYSL (residues 82-90 of HPV16 protein E6) SEQ ID NO:70
HYCYSLYGT (residues 85-93 of HPV16 protein E6) SEQ ID NO:71
CYSLYGTTL (residues 87-95 of HPV16 protein E6) SEQ ID NO:72
RFHNIRGRW (residues 131-139 of HPV16 protein E6) SEQ ID NO:73 and
RAHYNIVTF (residues 49-57 of HPV16 protein E7) SEQ ID NO:74;
wherein said amino acid sequence is derived from protein E6 or E7 of HPV16; and
wherein said peptide has the ability to bind to human MHC Class I allele HLA-A24.
7. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
8. A pharmaceutical composition comprising the peptide of claim 2 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
9. A pharmaceutical composition comprising the peptide of claim 3 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
10. A pharmaceutical composition comprising the peptide of claim 4 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
11. A pharmaceutical composition comprising the peptide of claim 5 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
12. A pharmaceutical composition comprising the peptide of claim 6 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.